Company Quick10K Filing
Allergan
10-K 2019-12-31 Filed 2020-02-18
10-Q 2019-09-30 Filed 2019-11-05
10-Q 2019-06-30 Filed 2019-08-08
10-Q 2019-03-31 Filed 2019-05-07
10-K 2018-12-31 Filed 2019-02-15
10-Q 2018-09-30 Filed 2018-10-31
10-Q 2018-06-30 Filed 2018-08-03
10-Q 2018-03-31 Filed 2018-05-03
10-K 2017-12-31 Filed 2018-02-16
10-Q 2017-09-30 Filed 2017-11-02
10-Q 2017-06-30 Filed 2017-08-09
10-Q 2017-03-31 Filed 2017-05-09
10-K 2016-12-31 Filed 2017-02-24
10-Q 2016-09-30 Filed 2016-11-04
10-Q 2016-06-30 Filed 2016-08-08
10-Q 2016-03-31 Filed 2016-05-10
10-K 2015-12-31 Filed 2016-02-26
10-Q 2015-09-30 Filed 2015-11-06
10-Q 2015-06-30 Filed 2015-08-06
10-Q 2015-03-31 Filed 2015-05-11
10-K 2014-12-31 Filed 2015-02-18
10-Q 2014-09-30 Filed 2014-11-05
10-Q 2014-06-30 Filed 2014-08-05
10-Q 2014-03-31 Filed 2014-05-05
10-K 2013-12-31 Filed 2014-02-25
10-Q 2013-09-30 Filed 2013-10-31
8-K 2020-03-17 Other Events, Exhibits
8-K 2020-03-03 Other Events, Exhibits
8-K 2020-02-10 Earnings, Exhibits
8-K 2020-01-27 Other Events, Exhibits
8-K 2019-11-05 Earnings, Exhibits
8-K 2019-11-05 Earnings, Exhibits
8-K 2019-10-14 Shareholder Vote, Other Events, Exhibits
8-K 2019-09-27 Other Events, Exhibits
8-K 2019-09-16 Regulation FD, Exhibits
8-K 2019-09-10 Other Events, Exhibits
8-K 2019-08-06 Earnings, Exhibits
8-K 2019-08-06 Earnings, Exhibits
8-K 2019-06-25 Enter Agreement, Regulation FD, Exhibits
8-K 2019-05-07 Earnings, Exhibits
8-K 2019-05-01 Shareholder Vote
8-K 2019-03-22 Other Events
8-K 2019-02-28 Other Events
8-K 2019-02-18 Officers, Other Events
8-K 2019-02-05 Other Events
8-K 2019-01-29 Earnings, Exhibits
8-K 2019-01-24 Other Events
8-K 2018-11-15 Enter Agreement, Exhibits
8-K 2018-11-08 Enter Agreement, Exhibits
8-K 2018-10-31 Regulation FD, Exhibits
8-K 2018-10-30 Earnings, Exhibits
8-K 2018-08-26 Officers
8-K 2018-08-05 Officers
8-K 2018-07-26 Earnings, Exhibits
8-K 2018-06-09 Officers
8-K 2018-05-02 Shareholder Vote
8-K 2018-04-30 Earnings, Exhibits
8-K 2018-02-08 Other Events
8-K 2018-02-06 Earnings, Exhibits
8-K 2018-02-05 Officers
8-K 2018-01-31 Earnings, Other Events
8-K 2018-01-08 Earnings, Regulation FD, Exhibits
8-K 2018-01-03 Earnings, Regulation FD
8-K 2018-01-01 Enter Agreement, Shareholder Rights, Exhibits

Allergan Financials

AGN Metrics, Comps, Filings

Quarterly | Annual

Business

Allergan plc was incorporated in Ireland on May 16, 2013 as a private limited company and re-registered effective September 20, 2013 as a public limited company. Except where otherwise indicated, and excluding certain insignificant cash and non-cash transactions at the Allergan plc level, the consolidated financial statements and disclosures are for two separate registrants, Allergan plc and Warner Chilcott Limited. The results of Warner Chilcott Limited are consolidated into the results of Allergan plc. Due to the deminimis activity between Allergan plc and Warner Chilcott Limited, references throughout this document relate to both Allergan plc and Warner Chilcott Limited. Refer to "Note 3 -Reconciliation of Warner Chilcott Limited results to Allergan plc results" in the accompanying "Notes to the Consolidated Financial Statements" in this document for a summary of the details on the differences between Allergan plc and Warner Chilcott Limited.

In August 2016 we completed the divestiture of our global generics business and certain other assets to Teva Pharmaceutical Industries Ltd. ("Teva") (the "Teva Transaction") for $33.3 billion in cash, net of cash acquired by Teva, which included estimated working capital and other contractual adjustments, and 100.3 million unregistered Teva ordinary shares (or American Depository Shares with respect thereto). As part of the Teva Transaction, Teva acquired our global generics business, including the United States ("U.S.") and international generic commercial units, our third-party supplier Medis, our global generic manufacturing operations, our global generic research and development ("R&D") unit, our international over-the-counter ("OTC") commercial unit (excluding OTC eye care products) and certain established international brands.

In October 2016, the Company completed the divestiture of the Anda Distribution business to Teva for $500.0 million. The Anda Distribution business distributed generic, branded, specialty and OTC pharmaceutical products from more than 300 manufacturers to retail independent and chain pharmacies, nursing homes, mail order pharmacies, hospitals, clinics and physician offices across the U.S.


Valuation ($BB)

Market Cap, Enterprise Value

Balance Sheet ($BB)

Assets, Stockholders' Equity

Income Statement ($BB Quarterly)

Revenue, Gross Profit, Net Income

Cash Flow ($BB Quarterly)

Operating, Investing, Financing

Comps ($MM TTM) Market Cap Gross Margin EV/EBITDA Ret on Assets Assets Liabilities Revenue G Profit Net Income EBITDA EV
AbbVie (ABBV) 109,786 77% 21.1 5% 59,441 67,667 32,867 25,412 3,255 6,259 132,264
Beigene (BGNE) 100,124 74% -123.1 -44% 1,881 587 430 318 -827 -807 99,328
Bristol Myers Squibb (BMY) 82,160 70% 10.6 10% 57,433 39,679 24,173 16,837 5,680 7,151 76,061
Celgene (CELG) 72,111 96% 10.4 14% 41,363 29,276 16,982 16,354 5,880 7,734 80,796
GW Pharmaceuticals (GWPH) 45,954 89% -870.1 -8% 848 128 205 182 -64 -52 45,400
Allergan (AGN) 54,957 63% -241.2 -5% 122,925 38,486 15,818 9,949 -5,872 -316 76,270
Zoetis (ZTS) 60,799 51% 29.1 13% 11,272 8,594 6,150 3,124 1,461 2,252 65,484
Sanofi (SNY) 52,845 0% 111,408 0 0 0 0 52,184
Vertex Pharmaceuticals (VRTX) 43,431 87% 46.7 29% 7,515 2,261 3,620 3,135 2,144 857 40,027
Regeneron Pharmaceuticals (REGN) 32,266 0% 12.2 15% 13,939 3,435 7,622 0 2,144 2,539 30,869
Alexion Pharmaceuticals (ALXN) 23,581 92% 12.8 10% 14,815 4,448 4,736 4,359 1,470 1,874 23,912
Biomarin Pharmaceutical (BMRN) 12,700 79% 1,194.1 -1% 4,558 1,484 1,250 986 -39 11 13,147
Elanco Animal Health (ELAN) 9,964 52% 30.6 1% 8,824 3,336 3,083 1,611 94 393 12,004
Mylan (MYL) 10,768 34% 12.5 -0% 31,054 19,590 8,309 2,810 -4 1,882 23,458
Teva (TEVA) 7,142 43% -10.6 -7% 57,246 42,322 17,455 7,550 -3,961 -2,814 29,713
Sarepta Therapeutics (SRPT) 5,588 0% -7.9 -36% 1,702 707 365 0 -620 -576 4,529
Ionis Pharmaceuticals (IONS) 8,784 76% 17.4 15% 2,895 1,397 821 626 436 491 8,536
Sage Therapeutics (SAGE) 7,414 82% -10.7 -56% 1,204 123 5 4 -670 -670 7,152
Bausch (BHC) 7,760 0% 25.3 -1% 31,667 29,107 8,498 0 -266 1,216 30,774
Alnylam Pharmaceuticals (ALNY) 8,913 80% -9.7 -32% 2,542 935 169 135 -821 -820 7,987

Balance Sheet ($MM)2013-09-302013-12-312014-03-312014-06-302014-09-302014-12-312015-03-312015-06-302015-09-302015-12-312016-03-312016-06-302016-09-302016-12-312017-03-312017-06-302017-09-302017-12-312018-03-312018-06-302018-09-302018-12-312019-03-312019-06-302019-09-30
Cash03293384,2943392502,1151,5182,0641,0962,2614907,5551,7241,0938871,6131,8179951,6751,1888807881,6511,238
Accounts Receivable1,4051,5091,5682,2292,3723,9934,4202,1432,4022,6532,4902,3982,5312,5422,7962,8092,8992,6392,7612,8272,8682,7313,0863,012
Inventory1,7861,7261,6332,6272,0763,1252,7861,2851,0101,0227277067189059369009049489228958479431,0041,083
PP&E2,5291,5811,5331,7042,6152,7982,8591,5704,0181,6021,5571,5662,0191,6591,7501,8022,4021,7701,7611,7572,5651,7811,8211,857
Assets022,72622,40425,78953,68252,789251,762251,540226,367237,785239,493236,725229,570207,619204,823189,428184,313178,757168,296164,900162,162146,310127,052123,846122,925
Accounts Payable493595589717645770971566369450437296225292304285324304286286350357518471
Long-Term Debt9,0528,45210,74315,09414,84642,70041,31940,64840,29338,55237,07532,75032,75031,75030,29630,38929,69826,03425,40623,61723,81323,55222,72622,550
Liabilities013,18912,77516,10524,68624,712161,158160,626130,576143,989145,398143,810122,288103,317106,00490,89690,10182,08273,41171,33269,59469,07339,50538,27338,486
Stockholders' Equity9,5329,6259,68029,14028,33171,40572,06977,47476,59177,45076,64490,31488,08682,82082,72478,63681,26679,72178,65677,92465,11461,54259,67558,475
Income Statement ($MM)2013-09-302013-12-312014-03-312014-06-302014-09-302014-12-312015-03-312015-06-302015-09-302015-12-312016-03-312016-06-302016-09-302016-12-312017-03-312017-06-302017-09-302017-12-312018-03-312018-06-302018-09-302018-12-312019-03-312019-06-302019-09-30
Revenue02,7792,6552,6673,6834,0574,2345,7554,0894,1983,7963,6853,6223,8643,5734,0074,0344,3263,6724,1243,9114,0803,5974,0904,051
Cost of Revenue482597498652639
Gross Profit3,6423,3153,0993,4383,412
R&D1721583923654314551,260431403636623913760489443408475689424435450474
SG&A05595621,2741,1981,4281,4611,0731,3261,1381,2101,1571,2771,1851,4681,170-2261,0961,1881,0451,1121,1981,994
Tax24486-103-62-22-45-28-10579-23-20915-10-3,9183630022110530218
Net Income0-14897294-1,043-733228545,308-62927956215,2711173-2533,32042160134-4,296-869-326-382
Cash Flow ($MM)2013-09-302013-12-312014-03-312014-06-302014-09-302014-12-312015-03-312015-06-302015-09-302015-12-312016-03-312016-06-302016-09-302016-12-312017-03-312017-06-302017-09-302017-12-312018-03-312018-06-302018-09-302018-12-312019-03-312019-06-302019-09-30
Cash Operating044047052281227,1401,9261,0485061,6681,382-1,092-832,6271,7011,4012,0483,5001,2401,4431,2921,4202,934
Cash Investing-24-154-4,454-738-12-25,470-252-2,356-1-8917,7506,7262,510386-482-7962,932702504289-100-2,822
Cash Financing0-3683,568-24-15935,286-1,456-248821368-3,062-9,595667-306-2,203-272-1,050500-1,283-2,432-152-1,121-240